The present study suggests that probiotics can provide protection against oxidative stress and apoptotic-related protein disregulation during experimentally induced colon carcinogenesis.

No abstract

The present study was undertaken to assess the effects of potential probiotics in regulating the activity of cyclooxygenase-2 (COX-2) along with other morphological and histological analysis during 1,2-dimethylhydrazine (DMH) induced colon carcinogenesis in rats. The rats were divided into 6 groups viz., normal control, Lactobacillus plantarum (AdF10) treated, Lactobacillus rhamnosus GG (LGG) treated, DMH treated, AdF10 + DMH treated and LGG + DMH treated. Probiotics were supplemented to rats at dose levels of 2 × 10(10) cells per day for 6 days in a week. All the treatments were continued for a period of 16 wk. DMH treatment resulted in a statistically significant increase in the levels of total sialic acid (TSA). However, on supplementation with probiotics, a significant reduction in TSA was observed. DMH treatment brought about a significant increase in the expression of COX-2. But, supplementation of probiotics brought down the protein expression to moderate level. Further, supplementation with probiotics was also able to reduce tumor incidence, tumor multiplicity and average tumor size. Therefore, treatment with probiotics has the potential of providing protection against colon cancer by suppressing the COX-2 expression as one of the protective mechanisms.

No abstract

ObjectivesIron oxide nanoparticles have been used to track the accumulation of chimeric antigen receptor (CAR) T cells with magnetic resonance imaging (MRI). However, the only nanoparticle available for clinical applications to date, ferumoxytol, has caused rare but severe anaphylactic reactions. MegaPro nanoparticles (MegaPro-NPs) provide an improved safety profile. We evaluated whether MegaPro-NPs can be applied for in vivo tracking of CAR T cells in a mouse model of glioblastoma multiforme.Materials and MethodsWe labeled tumor-targeted CD70CAR (8R-70CAR) T cells and non–tumor-targeted controls with MegaPro-NPs, followed by inductively coupled plasma optical emission spectroscopy, Prussian blue staining, and cell viability assays. Next, we treated 42 NRG mice bearing U87-MG/eGFP-fLuc glioblastoma multiforme xenografts with MegaPro-NP-labeled/unlabeled CAR T cells or labeled untargeted T cells and performed serial MRI, magnetic particle imaging, and histology studies. The Kruskal-Wallis test was conducted to evaluate overall group differences, and the Mann-Whitney U test was applied to compare the pairs of groups.ResultsMegaPro-NP-labeled CAR T cells demonstrated significantly increased iron uptake compared with unlabeled controls (P < 0.01). Cell viability, activation, and exhaustion markers were not significantly different between the 2 groups (P > 0.05). In vivo, tumor T2* relaxation times were significantly lower after treatment with MegaPro-NP-labeled CAR T cells compared with untargeted T cells (P < 0.01). There is no significant difference in tumor growth inhibition between mice injected with labeled and unlabeled CAR T cells.ConclusionsMegaPro-NPs can be used for in vivo tracking of CAR T cells. Because MegaPro-NPs recently completed phase II clinical trial investigation as an MRI contrast agent, MegaPro-NP is expected to be applied to track CAR T cells in cancer immunotherapy trials in the near future.